Aspen Pharmacare slumps 10% as stronger rand hits revenue
SA’s largest pharmaceutical company expects HEPS to rise 11%-15% in the year to end-June, with results capped by a stronger rand
04 September 2018 - 16:02
byKarl Gernetzky
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Pharmaceutical manufacturer Aspen Pharmacare said on Tuesday a stronger rand in the second half of its financial year weighed on revenue to the tune of R1bn.
In constant exchange-rate terms, revenue in the second half of the financial year was in line with the first half, but Aspen’s voluntary statement disappointed the market, sending its share price as much as 10% lower before losses were pared.
Headline earnings per share (HEPS) are expected to grow by between 11% and 15% to between R14.42 and R14.94, while earnings per share are expected to rise between 15% and 19% to between R12.92 and R13.37.
The company’s preferred measure of performance, normalised HEPS, are expected to rise between 8% and 12% to between R15.80 and R16.39.
Normalised HEPS adjusts for specific nontrading items.
Aspen’s share price has been under some pressure since 2015, with the company pursuing an aggressive growth strategy as it considers whether it should focus on generic medication or more specialist medication.
In the six months to end-December, the company had reported revenue of R21.9bn — an 11% rise from the previous comparative period. At the time, the company had flagged the risks of a stronger rand, noting that 80% of its sales were denominated in other currencies.
Aspen’s results to end-June are expected to be published on or about September 13.
At 10.30m Aspen’s share price had fallen 7.03% to R272.59, having lost 2.19% so far in 2018.
Correction: September 4 2018
An earlier version of this story referred to earnings instead of revenue in the first paragraph, and net HEPS rather than normalised HEPS in the fourth and fifth paragraphs. The HEPS amounts were also misstated.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Aspen Pharmacare slumps 10% as stronger rand hits revenue
SA’s largest pharmaceutical company expects HEPS to rise 11%-15% in the year to end-June, with results capped by a stronger rand
Pharmaceutical manufacturer Aspen Pharmacare said on Tuesday a stronger rand in the second half of its financial year weighed on revenue to the tune of R1bn.
In constant exchange-rate terms, revenue in the second half of the financial year was in line with the first half, but Aspen’s voluntary statement disappointed the market, sending its share price as much as 10% lower before losses were pared.
Headline earnings per share (HEPS) are expected to grow by between 11% and 15% to between R14.42 and R14.94, while earnings per share are expected to rise between 15% and 19% to between R12.92 and R13.37.
The company’s preferred measure of performance, normalised HEPS, are expected to rise between 8% and 12% to between R15.80 and R16.39.
Normalised HEPS adjusts for specific nontrading items.
Aspen’s share price has been under some pressure since 2015, with the company pursuing an aggressive growth strategy as it considers whether it should focus on generic medication or more specialist medication.
In the six months to end-December, the company had reported revenue of R21.9bn — an 11% rise from the previous comparative period. At the time, the company had flagged the risks of a stronger rand, noting that 80% of its sales were denominated in other currencies.
Aspen’s results to end-June are expected to be published on or about September 13.
At 10.30m Aspen’s share price had fallen 7.03% to R272.59, having lost 2.19% so far in 2018.
Correction: September 4 2018
An earlier version of this story referred to earnings instead of revenue in the first paragraph, and net HEPS rather than normalised HEPS in the fourth and fifth paragraphs. The HEPS amounts were also misstated.
GernetzkyK@businesslive.co.za
Companies in this Story
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Discovery’s emerging businesses pay off
Fund calls for full state control over where private sector doctors work
Big three will be the death of the day hospital sector, industry body warns
Listeriosis outbreak officially over, says Aaron Motsoaledi
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.